封面
市场调查报告书
商品编码
1668180

动脉粥状硬化药物市场 - 全球产业规模、份额、趋势、机会和预测,按诊断、按治疗、按给药途径、按最终用户、按地区和竞争进行细分,2020-2030 年预测

Atherosclerosis Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Diagnosis, By Treatment, By Route of Administration, By End User, By Region and Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2024 年全球动脉粥状硬化药物市场价值为 188.5 亿美元,预计到 2030 年将达到 228.4 亿美元,预测期内的年复合成长率(CAGR) 为 3.21%。动脉粥状硬化是一种因脂肪斑块堆积而导致动脉变窄和硬化的疾病,它仍然是全球重大的健康问题。它是心臟病、中风和其他心血管併发症的主要原因,每年导致数百万人死亡。随着动脉粥状硬化盛行率的不断上升,动脉粥状硬化药物市场也出现了大幅成长。

市场概况
预测期 2026-2030
2024 年市场规模 188.5 亿美元
2030 年市场规模 228.4 亿美元
2025-2030 年复合年增长率 3.21%
成长最快的领域 医院和诊所
最大的市场 北美洲

不良饮食、缺乏运动和吸烟等不健康的生活方式因素是导致全球动脉粥状硬化发病率上升的主要原因,导致大量患者需要治疗。此外,全球人口老化风险更高,预计将推动对动脉粥状硬化药物的需求。医疗技术和诊断技术的进步使得更早发现成为可能,有助于更及时地介入和治疗。公共卫生运动和人们对心血管健康的认识不断提高也鼓励了更多的人寻求治疗。

全球动脉粥状硬化药物市场虽然有重大机会,但也面临挑战。随着动脉粥状硬化负担的不断加重,持续的创新和研究对于开发有效的治疗方法至关重要。个人化医疗和针对性治疗可望改善患者的治疗效果。然而,必须解决与药品定价、患者依从性和日益激烈的竞争相关的挑战,以确保有需要的人能够获得药物。製药公司、医疗保健提供者和政策制定者之间的合作对于对抗动脉粥状硬化及其对全球健康的影响至关重要。

主要市场驱动因素

动脉粥状硬化盛行率上升

主要市场挑战

竞争加剧

主要市场趋势

技术进步

目录

第 1 章:产品概述

第 2 章:研究方法

第 3 章:执行摘要

第 4 章:顾客之声

第五章:全球动脉粥状硬化药物市场展望

  • 市场规模和预测
    • 按价值
  • 市场占有率和预测
    • 依诊断(踝臂指数、多普勒超音波、超音波心臟检查、心电图、血液检查、其他)
    • 依治疗方法(药物、手术、其他)
    • 依给药途径(口服、肠胃外、其他)
    • 按最终使用者(医院和诊所、门诊护理中心、其他)、按地区
    • 按地区
    • 按公司分类(2024)
  • 市场地图

第 6 章:北美动脉粥状硬化药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 北美:国家分析
    • 加拿大
    • 墨西哥

第 7 章:欧洲动脉粥状硬化药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 欧洲:国家分析
    • 英国
    • 义大利
    • 法国
    • 西班牙

第 8 章:亚太动脉粥状硬化药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 亚太地区:国家分析
    • 印度
    • 日本
    • 韩国
    • 澳洲

第 9 章:南美动脉粥状硬化药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • 南美洲:国家分析
    • 阿根廷
    • 哥伦比亚

第 10 章:中东和非洲动脉粥状硬化药物市场展望

  • 市场规模和预测
  • 市场占有率和预测
  • MEA:国家分析
    • 沙乌地阿拉伯
    • 阿联酋

第 11 章:市场动态

  • 驱动程式
  • 挑战

第 12 章:市场趋势与发展

  • 合併与收购(如有)
  • 产品发布(如果有)
  • 最新动态

第 13 章:波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 顾客的力量
  • 替代产品的威胁

第 14 章:竞争格局

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi SA
  • AstraZeneca Plc
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc

第 15 章:策略建议

第16章 调査会社について・免责事项

简介目录
Product Code: 18828

The Global Atherosclerosis Drugs Market was valued at USD 18.85 billion in 2024 and is projected to reach USD 22.84 billion by 2030, growing at a compound annual growth rate (CAGR) of 3.21% during the forecast period. Atherosclerosis, a condition characterized by the narrowing and hardening of arteries due to fatty plaque accumulation, continues to be a significant global health issue. It is a leading cause of heart disease, stroke, and other cardiovascular complications, resulting in millions of deaths annually. The market for atherosclerosis drugs has seen substantial growth, driven by the increasing prevalence of this condition.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 18.85 Billion
Market Size 2030USD 22.84 Billion
CAGR 2025-20303.21%
Fastest Growing SegmentHospitals & Clinics
Largest MarketNorth America

Unhealthy lifestyle factors such as poor diet, physical inactivity, and smoking are major contributors to the rising incidence of atherosclerosis worldwide, leading to a large patient population in need of treatment. Furthermore, the aging global population is at higher risk, which is expected to drive demand for atherosclerosis medications. Advances in medical technology and diagnostics have enabled earlier detection, facilitating more timely interventions and treatments. Public health campaigns and increasing awareness about cardiovascular health have also encouraged more individuals to seek treatment.

While the Global Atherosclerosis Drugs Market presents significant opportunities, it also faces challenges. With the rising burden of atherosclerosis, ongoing innovation and research are critical to developing effective therapies. Personalized medicine and targeted treatments show promise in improving patient outcomes. However, challenges related to drug pricing, patient adherence, and growing competition must be addressed to ensure accessibility for those in need. The collaboration between pharmaceutical companies, healthcare providers, and policymakers will be essential to combating atherosclerosis and its impact on global health.

Key Market Drivers

Rising Prevalence of Atherosclerosis

Atherosclerosis, characterized by plaque buildup in arteries, is becoming more widespread worldwide. This condition significantly increases the risk of heart attacks, strokes, and other cardiovascular diseases, making it a global healthcare priority. As modern lifestyles contribute to obesity, hypertension, and high cholesterol, the need for effective treatments for atherosclerosis is intensifying. Diets high in saturated fats, trans fats, and processed foods, common in many regions, further exacerbate the risk factors. Additionally, atherosclerosis is more prevalent in older individuals, and as the global population ages, the incidence of this condition is expected to rise, further stressing healthcare systems. Tobacco use and diabetes are also major contributors to the increasing prevalence of atherosclerosis.

Recent research has uncovered cancer-like features in atherosclerosis, highlighting potential new treatment avenues. Studies supported by the National Institutes of Health (NIH) suggest that smooth muscle cells in arteries may take on characteristics similar to cancer cells, worsening the condition. This discovery opens the door for novel therapies, such as using anti-cancer drugs to target these tumor-like processes, offering hope for more effective treatments.

Key Market Challenges

Increasing Competition

The atherosclerosis drugs market is highly competitive, with numerous established pharmaceutical companies and emerging players vying for market share. Major pharmaceutical companies like Pfizer, AstraZeneca, and Merck have dominated the market for years, benefiting from blockbuster drugs such as Lipitor (atorvastatin) and Crestor (rosuvastatin). However, newer entrants are introducing innovative therapies and specialized drug formulations targeting different aspects of atherosclerosis treatment. These companies are focusing on niche areas such as LDL cholesterol reduction or inflammation to address unmet needs in the market.

The rise of biosimilars and generics has further intensified competition, as these cost-effective alternatives to branded drugs become more prevalent. Smaller companies or startups face challenges related to regulatory approvals, clinical trials, and securing adequate funding. The dominance of established market leaders adds to the difficulty for newcomers to differentiate themselves. To remain competitive, companies must focus on innovation, whether through new drug formulations, strategic partnerships, or acquisitions.

Key Market Trends

Technological Advancements

Technological progress in healthcare is revolutionizing the development, diagnosis, and treatment of atherosclerosis, which is contributing to the growth of the market. Modern imaging technologies such as CT angiography, MRI, and intravascular ultrasound (IVUS) provide high-resolution images of blood vessels, enabling more accurate assessment of plaque buildup and its severity. Additionally, blood tests that incorporate biomarkers like high-sensitivity C-reactive protein (hs-CRP) and lipoprotein-associated phospholipase A2 (Lp-PLA2) aid in the early detection and risk assessment of atherosclerosis.

Artificial intelligence (AI) and machine learning are also enhancing the diagnosis of atherosclerosis by analyzing medical imaging and patient data to identify patterns and predict disease progression. These advancements are improving both the accuracy and efficiency of diagnosing atherosclerosis, contributing to better patient outcomes.

Key Market Players

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Merck & Co. Inc.
  • Pfizer Inc.
  • Eli Lilly and Co.
  • Sanofi S.A.
  • AstraZeneca Plc
  • Bayer AG
  • Regeneron Pharmaceuticals Inc.
  • GSK Plc

Report Scope

This report segments the Global Atherosclerosis Drugs Market into the following categories:

  • Diagnosis
  • Ankle-brachial Index
  • Doppler Ultrasound
  • Echocardiogram
  • Electrocardiogram
  • Blood Tests
  • Others
  • Treatment
  • Medication
  • Surgery
  • Others
  • Route of Administration
  • Oral
  • Parenteral
  • Others
  • End User
  • Hospitals & Clinics
  • Ambulatory Care Centers
  • Others
  • Region
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

The report includes detailed profiles of major companies in the atherosclerosis drugs market, offering insights into their market strategies and financial performance.

Available Customizations

The Global Atherosclerosis Drugs Market report can be customized to meet specific company needs, including detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Atherosclerosis Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Diagnosis (Ankle-brachial Index, Doppler Ultrasound, Echocardiogram, Electrocardiogram, Blood Tests, Others)
    • 5.2.2. By Treatment (Medication, Surgery, Others)
    • 5.2.3. By Route of Administration (Oral, Parenteral, Others)
    • 5.2.4. By End User (Hospitals & Clinics, Ambulatory Care Centers, Others),By Region
    • 5.2.5. By Region
    • 5.2.6. By Company (2024)
  • 5.3. Market Map

6. North America Atherosclerosis Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Diagnosis
    • 6.2.2. By Treatment
    • 6.2.3. By Route of Administration
    • 6.2.4. By End User
    • 6.2.5. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Atherosclerosis Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Diagnosis
        • 6.3.1.2.2. By Treatment
        • 6.3.1.2.3. By Route of Administration
        • 6.3.1.2.4. By End User
    • 6.3.2. Canada Atherosclerosis Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Diagnosis
        • 6.3.2.2.2. By Treatment
        • 6.3.2.2.3. By Route of Administration
        • 6.3.2.2.4. By End User
    • 6.3.3. Mexico Atherosclerosis Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Diagnosis
        • 6.3.3.2.2. By Treatment
        • 6.3.3.2.3. By Route of Administration
        • 6.3.3.2.4. By End User

7. Europe Atherosclerosis Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Diagnosis
    • 7.2.2. By Treatment
    • 7.2.3. By Route of Administration
    • 7.2.4. By End User
    • 7.2.5. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Atherosclerosis Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Diagnosis
        • 7.3.1.2.2. By Treatment
        • 7.3.1.2.3. By Route of Administration
        • 7.3.1.2.4. By End User
    • 7.3.2. United Kingdom Atherosclerosis Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Diagnosis
        • 7.3.2.2.2. By Treatment
        • 7.3.2.2.3. By Route of Administration
        • 7.3.2.2.4. By End User
    • 7.3.3. Italy Atherosclerosis Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Diagnosis
        • 7.3.3.2.2. By Treatment
        • 7.3.3.2.3. By Route of Administration
        • 7.3.3.2.4. By End User
    • 7.3.4. France Atherosclerosis Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Diagnosis
        • 7.3.4.2.2. By Treatment
        • 7.3.4.2.3. By Route of Administration
        • 7.3.4.2.4. By End User
    • 7.3.5. Spain Atherosclerosis Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Diagnosis
        • 7.3.5.2.2. By Treatment
        • 7.3.5.2.3. By Route of Administration
        • 7.3.5.2.4. By End User

8. Asia-Pacific Atherosclerosis Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Diagnosis
    • 8.2.2. By Treatment
    • 8.2.3. By Route of Administration
    • 8.2.4. By End User
    • 8.2.5. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Atherosclerosis Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Diagnosis
        • 8.3.1.2.2. By Treatment
        • 8.3.1.2.3. By Route of Administration
        • 8.3.1.2.4. By End User
    • 8.3.2. India Atherosclerosis Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Diagnosis
        • 8.3.2.2.2. By Treatment
        • 8.3.2.2.3. By Route of Administration
        • 8.3.2.2.4. By End User
    • 8.3.3. Japan Atherosclerosis Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Diagnosis
        • 8.3.3.2.2. By Treatment
        • 8.3.3.2.3. By Route of Administration
        • 8.3.3.2.4. By End User
    • 8.3.4. South Korea Atherosclerosis Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Diagnosis
        • 8.3.4.2.2. By Treatment
        • 8.3.4.2.3. By Route of Administration
        • 8.3.4.2.4. By End User
    • 8.3.5. Australia Atherosclerosis Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Diagnosis
        • 8.3.5.2.2. By Treatment
        • 8.3.5.2.3. By Route of Administration
        • 8.3.5.2.4. By End User

9. South America Atherosclerosis Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Diagnosis
    • 9.2.2. By Treatment
    • 9.2.3. By Route of Administration
    • 9.2.4. By End User
    • 9.2.5. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Atherosclerosis Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Diagnosis
        • 9.3.1.2.2. By Treatment
        • 9.3.1.2.3. By Route of Administration
        • 9.3.1.2.4. By End User
    • 9.3.2. Argentina Atherosclerosis Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Diagnosis
        • 9.3.2.2.2. By Treatment
        • 9.3.2.2.3. By Route of Administration
        • 9.3.2.2.4. By End User
    • 9.3.3. Colombia Atherosclerosis Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Diagnosis
        • 9.3.3.2.2. By Treatment
        • 9.3.3.2.3. By Route of Administration
        • 9.3.3.2.4. By End User

10. Middle East and Africa Atherosclerosis Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Diagnosis
    • 10.2.2. By Treatment
    • 10.2.3. By Route of Administration
    • 10.2.4. By End User
    • 10.2.5. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Atherosclerosis Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Diagnosis
        • 10.3.1.2.2. By Treatment
        • 10.3.1.2.3. By Route of Administration
        • 10.3.1.2.4. By End User
    • 10.3.2. Saudi Arabia Atherosclerosis Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Diagnosis
        • 10.3.2.2.2. By Treatment
        • 10.3.2.2.3. By Route of Administration
        • 10.3.2.2.4. By End User
    • 10.3.3. UAE Atherosclerosis Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Diagnosis
        • 10.3.3.2.2. By Treatment
        • 10.3.3.2.3. By Route of Administration
        • 10.3.3.2.4. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. F. Hoffmann-La Roche Ltd
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Novartis AG
  • 14.3. Merck & Co. Inc.
  • 14.4. Pfizer Inc.
  • 14.5. Eli Lilly and Co.
  • 14.6. Sanofi S.A.
  • 14.7. AstraZeneca Plc
  • 14.8. Bayer AG
  • 14.9. Regeneron Pharmaceuticals Inc.
  • 14.10. GSK Plc

15. Strategic Recommendations

16. About Us & Disclaimer